

NEWSLETTER

2026.Q2 | vol. 02

HSP Hsinchu Science Park
<https://www.sipa.gov.tw/>



About us

The Hsinchu Science Park (HSP) was initiated in 1980. Under the jurisdiction of the National Science and Technology Council, the Hsinchu Science Park Bureau (HSPB) is given the responsibility of developing, operating and managing the park.

Prospects

- Providing top-tier infrastructure and comprehensive one-stop services.
- Promoting industry-academia R&D collaboration.
- Creating a cluster of innovative ventures in the world arena.

HSP Highlights of the Quarter

Welcome New Companies to the Hsinchu Science Park

The 29th meeting of the Science Park Investment Review Committee of the National Science and Technology Council, held on December 23, 2025, approved four new investors, with a total investment of NT\$160 million:

1. Ayar Labs, Inc. Taiwan Branch (located at the Hsinchu Science Park) brings in an investment amount of NT\$150 million. Main products include optical I/O chiplets, multi-channel light sources and optical interconnect solutions; and integrated silicon photonics (SiPh) packaging solutions.
2. SAMJI Technology Co., Ltd., (located at the Yilan Science Park) brings in an investment amount of NT\$0.1 billion and main products include conductive film etching paste and solvent-free UV type OCA (optical transparent adhesive).
3. Energy Storage and Charging Equipment Certification Center of the Metal Industries Research & Development Centre (located at the Tongluo Science Park) establishes an energy storage and charging equipment certification center, primarily providing safety testing services for lithium battery products and establishing testing technologies for charging equipment.
4. The Biomedical Accelerator of the Industrial

Technology Research Institute (located at the Biomedical Science Park) establishes a biomedical accelerator, with an estimated annual operating investment of approximately NT\$24 million, aiming at building a national team in biomedicine, with an eye to promote sustainable development of a national-level biomedical acceleration platform. The accelerator employs a strategy based on three main axes: "connectivity, incubation, and internationalization," providing one-stop acceleration services in fields such as electronic medical devices, testing equipment, biomedical materials, and drug development.

The 30th meeting of the Science Park Investment Review Committee of the National Science and Technology Council, held on January 29, 2026, six new investors were approved, with a total investment of NT\$1.236 billion:

1. Tianhan Technology Co., Ltd. invests NT\$800 million, covering grid-type data storage systems, dedicated networks for slicing industry, and intelligent edge computing devices.
2. Phison Electronics Co., Ltd. Hsinchu Branch invests NT\$206 million, covering AI-powered intelligent diagnosis and treatment assistance system.

3. Biotaitan Molmed Co., Ltd. Hsinchu Branch invests NT\$120 million, covering rapid nucleic acid testing instruments, miniature rapid sample preparation instruments, multi-standard testing reagents and consumables, drug sensitivity testing instruments, and AI-assisted analysis services.
4. L.S.E. Semiconductors Corp. Hsinchu Branch invests NT\$50 million, covering electronic control software for semiconductor exposure machines, electronic control software for coating and developing machines, and electronic control software for testing equipment, which complement the semiconductor equipment produced by its parent company.
5. Hopson Innovative Biotechnology Co., Ltd. Yilan Branch invests NT\$20 million, covering zero-petroleum laundry detergent, zero-petroleum all-purpose household cleaning liquid, and the research and development of iNUCLEAN smart

refill station combined with Internet of Things (IoT) technology.

6. Chakou Scientific Research Enterprise Co., Ltd. invests NT\$0.4 billion, covering carbon crystal plant protection agent, carbon crystal agricultural product preservative agent, methyl crystal soil modifier, and waste wood regenerated mushroom space pack.

The 31st meeting of the Science Park Investment Review Committee of the National Science and Technology Council, held on March 25, 2026, approved two new investors, with a total investment of NT\$310 million:

1. Pulsaris AI, Inc. invests NT\$300 million, covering semiconductor layout optimization software tool that combined AI and EDA algorithms.
2. Dayi Health Research Co., Ltd. invests NT\$10 million, covering innovation and development of health food raw materials and the optimization of powder dosage forms.

HSP Power - Startup Team Introduction

Anivance AI Rides with Global Trend Advancing the Future of Organ Chips at the Hsinchu Science Park

A blizzard sparks the birth of Anivance AI: Dr. Chen Guan-yu, founder of Anivance AI, his initial inspiration for developing organ-on-a-chip technology began in Boston, USA, in 2014, while he was in a blizzard, preparing to move to the classroom to conduct an animal experiment at MIT. The biting snow stirred a thought in his mind: "Is there a way to obtain data without conducting animal experiments?" This unique event drove Dr. Chen Guan-yu towards research on organ-on-a-chip technology. However, the true entrepreneurial spirit sparked in his mind was related to his "teacher's soul."

In 2015, after returning to Taiwan, Dr. Chen Guan-yu took a teaching position at National Chiao Tung University. As a professor, he observed that despite having equally excellent students, those with a "life sciences" background often ended up significantly inferior career paths and incomes after graduation compared to other classmates choosing the semiconductor

Anivance AI

A startup team originating from National Yangming Chiao Tung University, focusing on the development of "organ chips" and the integration of artificial intelligence technologies.



■ Anivance AI team photo



■ Anivance AI Founder & CEO Guan Yu Chen, Ph.D.

industry as their careers. An idea touched him: "Is it possible to create an industry spanning biomedicine and technology, allowing these talents to receive the compensation and opportunities they deserve?" Against this backdrop, "Anivance AI" was born. Naming concept of "Anivance AI", Dr. Chen Guan-yu shared that Taiwanese company title "Kiulang" is derived from the Taiwanese pronunciation of "save people" (kiù-lâng), symbolizing the initial aspiration to dedicate oneself to the smart healthcare industry. On the other hand, "Kiulang" also embodies the expectation for internal partners: in the rapidly iterating technology industry, the pursuit is not a fleeting wave, but a long-lasting wave that can sustain progress.

In 2025, Anivance AI officially moved into the Hsinchu Science Park, establishing a research and development center at the biomedical park. The witnessing the thriving "Hsinchu Science Park semiconductor industry ecosystem" and the great facilities at the biomedical park (e.g. hospitals, pharmaceutical companies, and related institutions), which act as a great surrounding for implementing chips with biomedical solutions. Furthermore, the value of this diverse ecosystem is also reflected in the cross-team and cross-industry communication and collaboration. Dr. Chen added, "The 'Hsinchu Science Park Ecosystem' brings together many high-quality teams, providing opportunities to connect with better supply chains and create substantial collaborations. It also allows them to learn different business strategies through exchanges with other teams. These are invaluable resources for startups." Reflecting on the initial application process to join the Hsinchu Science Park, Dr. Chen indicated that the system and processes were well-established, and there was a corresponding mentoring mechanism, allowing startups that had to race against time to quickly establish themselves and focus on development. In July 2025, Anivance AI participated in the "Hsinchu Science Park Startup Exchange Matching and Business Opportunity Linking Program Selection" organized by the Science Park Bureau. Along with seven other outstanding startups, they traveled to Singapore to participate in the "Singapore Technology Week (SWITCH)" exhibition. This experience not only forged Dr. Chen's partnership with other startups but also successfully connected them with Singaporean buyers, resulting in a recent order.



Anivance AI product model



Anivance AI exhibition area

Trust Bio-sonics, Inc. Expands Horizons: Lipid Microsphere Imaging Paves the Way for Precision Diagnostics

The story of Dr. Wang Chung-Hsin's involvement in medical ultrasound research begins at Tsinghua University. At that time, in the ultrasound imaging laboratory at

Tsinghua University, Dr. Wang, then a doctoral student, and his lab partners devoted themselves to research related to "imaging," dedicated to developing Taiwan's own contrast agent technology.

In 2012, Dr. Wang received the National Innovation Award from the Biotechnology Industry Development Council

Trust Bio-sonics

An innovative R&D pharmaceutical company specializing in "liposome technology," focusing on the development of specialized diagnostic drugs and next-generation drug delivery platform technologies. Its proprietary liposome formation technology provides small-particle-size and highly stable microbubble injection formulations.

Trust Bio-sonics General Manager Chung-Hsin Wang, Ph.D.



for his "Ultrasound Imaging Contrast Agent Platform," and obtained his doctoral degree in the same year. Dr. Wang recalls that receiving the National Innovation Award was not only an affirmation, but more importantly, the market analysis and industry assessment conducted during the award application process allowed him to clearly see the urgent market demand. After winning the award, the proactive contact from ultrasound equipment manufacturers became a crucial opportunity to extend the laboratory's technology. With the help of equipment suppliers, Dr. Wang Chung-Hsin frequently visited various medical institutions, discussing the practical applications and needs of contrast agents with physicians at medical centers. It was during this period that he and his partners resolved to industrialize their technology and formally establish the company—the starting point for Trust Bio-sonics (hereinafter referred to as Trust).



Trust Bio-sonics team photo



Product simulation



Trust Bio-sonics product sample

In its early days, Trust conducted research at the Tsinghua University Innovation Incubation Center. Dr. Wang recalled that a mentor reminded them that if they wanted the company to truly grow and thrive, they must eventually leave the campus and face the industry. This reminder became a crucial turning point for the team. Therefore, in its early stages, Trust successively moved into the Taiwan Supra Integration and Incubation Center (Si2C) and the Small and Medium Enterprise Innovation Incubation Center at the Hsinchu Biomedical Science Park, gradually moving its technology from the academic research system to a more complete industrial environment, laying the foundation for future development and overcoming the arduous early development process with the help of the incubation center's equipment resources.

In recent years, Trust has grown from a startup with 6 core members to a professional team of over 20. The research focus of its "liposome imaging technology" has also expanded from its initial focus on ultrasound diagnostic applications to the field of cancer treatment that enhances drug delivery. In February 2025, with the approval of the National Science and Technology Council, Trust officially transitioned to a scientific enterprise and settled at the Hsinchu Biomedical Science Park, becoming the startup with the highest approved investment amount at that time.

Dr. Wang stated that this achievement is not only a financial gain but also a substantial affirmation of the team's long-term dedication, further solidifying their confidence that their developed products are addressing real and concrete needs in clinical settings. Having established itself at the Hsinchu Science Park from the outset, Trust has not only witnessed the gradual improvement of the biomedical park's space and functions but also experienced the clustering effect of more and more industry partners joining. Dr. Wang stated that this industry chain provides the team with a platform for exchange, resource integration, and business cooperation, which is particularly helpful for the growth and advancement of a startup team. Looking ahead, Trust's ambitions extend beyond the local market. As its technology matures, the team will expand its products to healthcare systems worldwide, including the United States, Japan, South Korea, and Southeast Asia.



Hsinchu Science
Park Newsletter